Endo International (NSDQ:ENDP) said today that it will cut 90 full-time positions from its workforce in an effort to restructure its generics and U.S. branded pharmaceutical businesses.
The company said it will invest part of the cost savings that result from its restructuring into Endo’s core products and new product development.
In early December, BioDelivery Sciences International (NSDQ:BDSI) reacquired the license to the Belbuca (buprenorphine) buccal film from Endo. Malvern, Penn-based Endo Pharmaceuticals licensed the worldwide manufacturing and marketing rights to the opioid patch from BioDelivery in 2012.
Get the full story at our sister site, Drug Delivery Business News.
The post Endo cuts staff in restructuring effort appeared first on MassDevice.
from MassDevice http://ift.tt/2jW7KT7
Cap comentari:
Publica un comentari a l'entrada